9/21/2022 1:18:30 AM
Argenx Submits BLA To FDA For Subcutaneous Efgartigimod For Generalized Myasthenia Gravis
6/24/2022 1:35:02 AM
Argenx Gets Positive CHMP Opinion For Efgartigimod For Patients With Generalized Myasthenia Gravis In Europe
4/1/2022 1:04:47 AM
Argenx To Present New Data From Generalized Myasthenia Gravis Program At 2022 AAN Annual Meeting
3/22/2022 2:06:14 AM
Argenx Reports Positive Phase 3 Data From Study Evaluating Subcutaneous Efgartigimod For Generalized Myasthenia Gravis
3/3/2022 2:00:18 AM
Argenx FY Loss Per Share $7.99 Vs Loss $13.40 Last Year
1/20/2022 2:19:11 AM
Argenx Announces VYVGART Approval In Japan For Treatment Of Generalized Myasthenia Gravis
1/7/2022 1:08:07 AM
Argenx Says On Track For Global Commercial Launch Of VYVGART For Treatment Of Generalized Myasthenia Gravis
8/25/2021 1:07:12 AM
Argenx Announces Validation Of EMA Application For Efgartigimod In Generalized Myasthenia Gravis
5/14/2021 1:44:36 AM
Argenx Q1 Loss/Shr $0.81 Vs Loss $2.06 Last Year
2/2/2021 9:41:58 AM
Argenx Says Not Aware Of Any Elevation Of Cholesterol Markers Related To Treatment With Efgartigimod
12/4/2018 7:49:18 AM
Wedbush Reiterates argenx SE (ARGX) At Outperform With $131 Up From $130 Price Target